Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY-NC-ND 4.0Annals of Hematology

Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies

  1. 1Department of Children Hematological Oncology, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Jiangyang District, Luzhou, Sichuan 646000 China

Abstract

Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy in children, with molecular alterations playing critical roles in disease development and therapeutic responses. The CBFA2T3::GLIS2 (C/G) is the most frequent genetic alteration identified in non-Down syndrome acute megakaryoblastic leukemia (AMKL) and results from a cryptic inversion involving the subtelomeric region of chromosome 16. Multiple chimeric transcripts can be generated depending on the breakpoint location, with CBFA2T3-ex11/GLIS2-ex3 being the predominant transcript. This fusion gene is associated with chemotherapy resistance and an unfavorable clinical outcome. Although initially identified in AMKL, it has also been detected in several cytogenetically normal AML subtypes, including M0, M1, M2, M4, and M5. However, the molecular mechanisms underlying C/G fusion-driven leukemogenesis remain incompletely characterized. This review provides an overview of the pathogenic mechanisms, emerging therapeutic strategies, and clinical challenges associated with C/G-positive pediatric AML.

Related

  1. Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
    Michelle Diane Rudman, Jason D. Ulrich, David M. Holtzman
    CellPeer-reviewedCC BY-NC-ND13 citedNeurosciencePhysiologyOpenAlex
  2. Advances in Multi-Omics Research on Post-Stroke Depression: From Molecular Mechanisms to Therapeutic Strategies.
    Guoxun Feng, Lei Gao, Yuanzhi Zhao +4
    Neuropsychiatric disease and treatmentPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCPMC
  3. Molecular Mechanisms and Therapeutic Advances in KRAS G12C‐Mutant Non‐Small Cell Lung Cancer: Toward Mechanism‐Guided Longitudinal Management
    Haiying Wang, Hanxiao Chen, Sheng Li +1
    Cancer innovationPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Lactylation in liver fibrosis: from molecular mechanisms to targeted therapeutic strategies
    Zhiwei Dong, Feibo Xu, Mei Ye +1
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  5. Molecular mechanisms for sustaining cancer stem cells characteristics and targeted therapeutic strategies
    Chen-xi Zhao, Shu-yun Wang, Ke Li
    Acta Pharmacologica SinicaPeer-reviewedLicence not statedFull text2 citedOncologyPMC
BibTeX
@article{she2026advances,
  title = {{Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies}},
  author = {Jiatong She and Ling Guo and You Yang and Jing Liu and Rui Zhang and Yan Liu and Huazhang Guo and Yangyang Huang and Wenjun Liu},
  journal = {Annals of Hematology},
  year = {2026},
  month = aug,
  doi = {10.1007/s00277-026-07227-2},
  url = {https://doi.org/10.1007/s00277-026-07227-2},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies
AU  - Jiatong She
AU  - Ling Guo
AU  - You Yang
AU  - Jing Liu
AU  - Rui Zhang
AU  - Yan Liu
AU  - Huazhang Guo
AU  - Yangyang Huang
AU  - Wenjun Liu
PY  - 2026
DA  - 2026/08/13
JO  - Annals of Hematology
DO  - 10.1007/s00277-026-07227-2
UR  - https://doi.org/10.1007/s00277-026-07227-2
AB  - Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy in children, with molecular alterations playing critical roles in disease development and therapeutic responses. The CBFA2T3::GLIS2 (C/G) is the most frequent genetic alteration identified in non-Down syndrome acute megakaryoblastic leukemia (AMKL) and results from a cryptic inversion involving the subtelomeric region of chromosome 16. Multiple chimeric transcripts can be generated depending on the breakpoint location, with CBFA2T3-ex11/GLIS2-ex3 being the predominant transcript. This fusion gene is associated with chemotherapy resistance and an unfavorable clinical outcome. Although initially identified in AMKL, it has also been detected in several cytogenetically normal AML subtypes, including M0, M1, M2, M4, and M5. However, the molecular mechanisms underlying C/G fusion-driven leukemogenesis remain incompletely characterized. This review provides an overview of the pathogenic mechanisms, emerging therapeutic strategies, and clinical challenges associated with C/G-positive pediatric AML.
SN  - 0939-5555
SN  - 1432-0584
ER  -